pilot replicate design [RSABE / ABEL]

posted by Helmut Homepage – Vienna, Austria, 2014-11-19 16:18 (4241 d 16:48 ago) – Posting: # 13883
Views: 10,986

Hi Khaoula,

I agree with ElMaestro. The FDA requires 24 dosed subjects in replicate studies intended for RSABE, but only for the pivotal studies. The number of eligible subjects can be lower.

As usual the impact of the ratio on the estimated sample size of the pivotal study is higher than the one of the CV (which is taken care in RSABE anyway). Therefore, I would not design the pilot in a small number of subjects. For HVDs the GMR jumps around like crazy between studies. Don’t be tempted to assume a GMR too close to 1 even if you observed it in a pilot. That’s why the two Lászlós suggested a GMR of 0.9 in study planning.

Dif-tor heh smusma 🖖🏼 Довге життя Україна! [image]
Helmut Schütz
[image]

The quality of responses received is directly proportional to the quality of the question asked. 🚮
Science Quotes

Complete thread:

UA Flag
Activity
 Admin contact
23,656 posts in 4,994 threads, 1,571 registered users;
271 visitors (0 registered, 271 guests [including 19 identified bots]).
Forum time: 10:07 CEST (Europe/Vienna)

Try to learn something about everything
and everything about something.    Thomas Henry Huxley

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5